The briefing
University of Otago researchers report that metformin, a common type 2 diabetes medication, is associated with a reduced risk of prostate cancer. The finding emerged from a large multi‑year analysis and adds to evidence of metformin’s potential protective effects beyond blood sugar control.
Original headline
Diabetes drug cuts prostate cancer risk